There are 2867 resources available
1018P - Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients
Presenter: Rajwanth Veluswamy
Session: Poster session 14
1019P - Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 14
1020P - Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: The RECLAIM study
Presenter: Idris Bahce
Session: Poster session 14
1021P - DURATION - a phase II randomized trial in older / frail patients (pts) with advanced non-small cell lung cancer (NSCLC) comparing chemotherapy (CTX, 4 cycles) with CTX (2 cycles) and consecutive durvalumab (D): Top-line early efficacy endpoints
Presenter: Jonas Kuon
Session: Poster session 14
1022P - A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed first line treatment
Presenter: Caicun Zhou
Session: Poster session 14
1024P - Net treatment benefit of OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
Presenter: Marc Buyse
Session: Poster session 14